{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3807.3","upperLimit":"8789.4","value":"5030"},{"groupId":"OG001","lowerLimit":"3660.5","upperLimit":"7285.5","value":"4656.8"},{"groupId":"OG002","lowerLimit":"2355.9","upperLimit":"4889.3","value":"2602.4"},{"groupId":"OG003","lowerLimit":"5401.1","upperLimit":"9161.2","value":"6173.2"},{"groupId":"OG004","lowerLimit":"4718.0","upperLimit":"8665.6","value":"7135.9"},{"groupId":"OG005","lowerLimit":"2154.7","upperLimit":"10151.4","value":"4666.9"},{"groupId":"OG006","lowerLimit":"2028.5","upperLimit":"3377.1","value":"3132.8"},{"groupId":"OG007","lowerLimit":"4739.7","upperLimit":"8809.0","value":"6505.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"description":"The median (min, max) of the area under the drug concentration curve evaluated at 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose on day 1 for Selinexor by study part, schema, and dose level.","dispersionType":"Full Range","groups":[{"description":"35 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course (Pre-amendment #1)","id":"OG000","title":"Part A: Dose Level 1"},{"description":"35 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course (Amendment 1)","id":"OG001","title":"Part A: Dose Level 1 (DL 1)"},{"description":"20 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course","id":"OG002","title":"Part A: Dose Level -1 (DL -1)"},{"description":"45 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG003","title":"Part A: Weekly Dose Level 1 (WDL 1)"},{"description":"35 mg/m2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG004","title":"Part A: Weekly Dose Level -1 (WDL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG005","title":"Part B: Weekly Dose Level -1 (WDL -1)"},{"description":"20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course","id":"OG006","title":"Part PK: Dose Level -1 (DL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG007","title":"Part PK: Weekly Dose Level -1 (WDL -1)"}],"paramType":"MEDIAN","populationDescription":"All eligible patients","reportingStatus":"POSTED","timeFrame":"Up to 2 days","title":"Area Under the Drug Concentration Curve of Selinexor","type":"PRIMARY","unitOfMeasure":"h*ng/ml"}